Yuewei Li, PhD, is a Lab Technologist in our Clinical Genomics Lab. Dr. Li focuses on the development of new assays to detect rare mutants with Droplet Digital PCR (ddPCR) and to detect the gene translocation and amplification with Fluorescence in situ hybridization (FISH), compensating for limitations of our Next Generation Sequencing (NGS) assays. She also conducts DNA and RNA library preparation using HaloPlex Target Enrichment System, SureSelectXT Target Enrichment System, Truseq Stranded mRNA Sample Preparation, Truseq Stranded Total RNA Sample Preparation, and conducts sequencing Libraries with Hiseq2500 sequencer. She performs qualification and quantification of DNA &RNA samples (Tape station, Bioanalyzer, and Qubit), and has helped with automated isolation of genomic DNA. Dr. Li is also instrumental in the development of our clinical standard operating procedures. She has worked in the clinical genomics lab since 2015 as a clinical laboratory technologist and received a license as New York State of Clinical Laboratory Technologist in molecular diagnosis. Dr. Li received her PhD in Molecular Pharmacology & Toxicology at Kyorin University, Tokyo, Japan, where her thesis was Molecular identification and functional characterization of a novel transporter. During this time, she performed BLAST in EST database, and the molecular technologies such as DNA & mRNA extraction, DNA sub-cloning, RT-PCR and Northern blot, resulting in identification of a novel transporter. She also performed DNA sequencing, in situ hybridization, site-directed mutation, cRNA synthesis, xenopus oocyte injection, and double immunofluorescent staining, as well as IHC and western blot to characterize this novel transporter. After graduation, she worked in J-Pharma Co., Ltd, Tokyo, Japan as a scientist, where she was responsible for characterizing knockout mice of transporters; designing and optimizing in situ hybridization protocols; supervising team members on in-situ hybridization, and double immunoflourescent staining, as well as troubleshooting. From 2009- 2015, she worked in the Department of Pathology and Medicine at Weill Cornell Medicine as a postdoc and received a promotion to Research Associate. She completed a project studying the role of CUL4B ubiquitin ligase in tumor resistance to TOP1-directed chemotherapy drugs using the mouse xenograft model and in vitro cell culture, and a project of delineating the role of CUL4B in the pathobiology of X-linked intellectual disability using knockout mice. She also supervised technicians to conduct plasmid subcloning and make all knockout mice arrangements in the lab, including genotyping and designing mouse cross-mating, to ensure that the related projects worked efficiently.